{
    "clinical_study": {
        "@rank": "46887", 
        "acronym": "Gastro DOC", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "DOX 4 cycles - Surgery - Follow-up\nDOX:\nDocetaxel 35 mg/m2  day 1 and 8 by one hour infusion; Oxaliplatin  80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.\nTreatment should be administered for 4 cycles before surgery. Each cycle will be repeated every 3 weeks."
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental", 
                "description": "DOX 2 cycles - Surgery - DOX 2 cycles - Follow-up\nDOX:\nDocetaxel 35 mg/m2  day 1 and 8 by one hour infusion; Oxaliplatin  80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.\nTreatment should be administered for 2 cycles before surgery and for further 2 cycles after surgery, unless progression of disease or unacceptable toxicity occurs, or patient refusal.  In these cases patients will go off treatment.\nEach cycle will be repeated every 3 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "Title: A randomised phase II study of pre-operative or peri-operative docetaxel,\n      oxaliplatin, capecitabine (DOX) regimen in patients with locally advanced resectable gastric\n      cancer.\n\n      Clinical Phase: II\n\n      Study Objectives:\n\n      Primary:\n\n      The percentage of patients receiving all the planned chemotherapeutic cycles.\n\n      Secondary:\n\n        -  Downstaging according to Recist criteria\n\n        -  pT1-3 vs pT0.\n\n        -  Safety: number of patients with grade 3-4 toxicity\n\n        -  The role of PET Scan as predictor of response\n\n        -  Curative vs palliative surgery\n\n        -  TTP\n\n        -  OS\n\n        -  Diagnostic correlation between the various staging methods\n\n        -  Possible correlations between CT scan, CT/PET, laparoscopy;\n\n        -  Molecular markers related to toxicity: DPYD, MTHFR, TS, XPD, ERCC1, XRCC1;\n\n        -  Molecular markers related to prognosis: TYMS, GSTP1, COX-2, RUNX3, methylation profile\n           (Cox2, hMLH1, MGMT);\n\n        -  Molecular markers related to therapy response: TYMS, DPYD, MTHFR, OPRT, ERCC1,\n           XRCC1/2/3, GSTP1, GSTM1, GSTT1, ABCB1, methylation profile (Cox2, hMLH1, MGMT), whole\n           genome arrayCGH.\n\n      Study design:\n\n      Multicenter, randomized, open label phase II study Arm A: DOX 4 cycles - Surgery - Follow-up\n      Arm B: DOX 2 cycles - Surgery - DOX 2 cycles - Follow-up\n\n      Population:\n\n      Male or female, 18-75 years of age, with a diagnosis of histologically confirmed,\n      potentially resectable adenocarcinoma of the stomach.\n\n      Sample Size: Planned sample size is 90 patients, 45 patients for each arm (p0=50%, p1=80%,\n      alpha=0.05 (two sides), beta=0.2)\n\n      Treatment Plan:\n\n      Treatment will be administered for 4 and 2 cycles before surgery in arm A and B,\n      respectively, and in arm B for a further 2 cycles after surgery unless progression or\n      unacceptable toxicity occurs, or a patient refuses treatment. In such cases patients will go\n      off treatment. 3-6 weeks after the end of the fourth (arm A) or second (arm B) preoperative\n      cycle, patients will undergo surgery.\n\n      After surgery 3-6 weeks from surgery patients in arm B will receive 2 more cycles.\n\n      DOX: Docetaxel 35 mg/m2   day 1 and 8 Oxaliplatin  80 mg/m2 day 1 Capecitabine 750 mg/m2 x 2\n      daily for 2 weeks\n\n      Cycles repeated every 3 weeks\n\n      Evaluation criteria:  Tumor assessment will be performed according to the RECIST criteria\n      (version 1.1).\n\n      Duration of Study:\n\n      Overall study duration: 07/2010- 03/2017 Planned study duration per patient: 5 years"
        }, 
        "brief_title": "Study Of Pre-Operative Or Peri-Operative Docetaxel, Oxaliplatin, Capecitabine (Dox)Regimen In Patients With Locally Advanced Resectable Gastric Cancer", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed written informed consents\n\n          2. Male or female 18-75 years of age\n\n          3. Diagnosis of histologically confirmed, potentially resectable adenocarcinoma of the\n             stomach\n\n          4. cT3 subserosal - cT4a - cT4b (7th edition UICC TNM) or bulky lymph node metastases\n             independently of T\n\n          5. ECOG performance status of  0-1 at study entry\n\n          6. Laboratory requirements (\u2264 7 days prior chemotherapy start):\n\n               1. Hematology:\n\n                  I) Neutrophils > 1.5 x 109 /L II) Platelets > 100 x 109 /L III) Hemoglobin >\n                  10g/dL\n\n               2. Hepatic function I) Total bilirubin < 1.25 UNL II) AST (SGOT) and ALT (SGPT) <\n                  2.5xUNL III) Alkaline phosphatase < 2.5xUNL\n\n               3. Renal function I) Creatinine <1.5 UNL In the event of border-line values, the\n                  calculated creatinine clearance should be > 60 mL/min;\n\n                    -  Written informed consent signed and dated before randomization procedures,\n                       including expected cooperation of patients for treatment and follow-up,\n                       must be obtained and documented according to local regulatory requirements.\n\n                    -  Effective contraception for both male and female patients if the risk of\n                       conception exists\n\n        Exclusion Criteria:\n\n          1. Early gastric cancer (if N0)\n\n          2. T2 (according to 7th edition of UICC TNM) if N0\n\n          3. Linitis plastica\n\n          4. Positive peritoneal cytology\n\n          5. Distant metastases\n\n          6. Neoplasm involving the gastro-esophageal junction\n\n          7. Pertoneal involvement\n\n          8. Concurrent chronic systemic immune therapy\n\n          9. Any investigational agent(s) administered 4 weeks prior to entry\n\n         10. Clinically relevant coronary artery disease, a history of myocardial infarction or of\n             hypertension not controlled by therapy within the last 12 months\n\n         11. Known grade 3 or 4 allergic reaction to any of the components of the treatment\n\n         12. Known drug abuse/alcohol abuse\n\n         13. Legal incapacity or limited legal capacity\n\n         14. Medical or psychological condition which, in the opinion of the investigator, would\n             not permit the patient to complete the study or sign meaningful informed consent\n\n         15. Women who are pregnant or breastfeeding\n\n         16. Acute or subacute intestinal occlusion\n\n         17. Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ\n             of the cervix. (Patients with a previous malignancy but without evidence of disease\n             for \u2265 5 years will be allowed to enter the trial)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01876927", 
            "org_study_id": "IRST151.01", 
            "secondary_id": "2010-020189-37"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "intervention_name": "DOX 4 cycles - Surgery", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Arm B", 
                "intervention_name": "DOX  2 cycles - Surgery - DOX  2 cycles", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Docetaxel", 
                "Capecitabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Locally", 
            "Advanced", 
            "Resectable", 
            "Gastric Cancer"
        ], 
        "lastchanged_date": "June 11, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Stefano Cascinu, Prof."
                }, 
                "facility": {
                    "address": {
                        "city": "Ancona", 
                        "country": "Italy", 
                        "state": "AN"
                    }, 
                    "name": "Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - GM Lancisi"
                }, 
                "investigator": {
                    "last_name": "Stefano Cascinu, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Andrea Rinnovati, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bibbiena", 
                        "country": "Italy", 
                        "state": "AR"
                    }, 
                    "name": "USL 8 Arezzo - Presidio Ospedaliero Zona Casentino - Ospedale di Bibbiena"
                }, 
                "investigator": {
                    "last_name": "Andrea Rinnovati, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gianni Mura, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Valdarno (Montevarchi)", 
                        "country": "Italy", 
                        "state": "AR"
                    }, 
                    "name": "USL 8 Arezzo - Ospedale \"Santa Maria alla Gruccia\""
                }, 
                "investigator": {
                    "last_name": "Gianni Mura, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Silvia Ruscelli, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Cesena", 
                        "country": "Italy", 
                        "state": "FC"
                    }, 
                    "name": "Ospedale Bufalini"
                }, 
                "investigator": {
                    "last_name": "Silvia Ruscelli, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "o.nanni@irst.emr.it", 
                    "last_name": "Oriana Nanni, phD", 
                    "phone": "+390543739266"
                }, 
                "facility": {
                    "address": {
                        "city": "Meldola (FC)", 
                        "country": "Italy", 
                        "state": "FC", 
                        "zip": "47014"
                    }, 
                    "name": "Irccs Irst"
                }, 
                "investigator": {
                    "last_name": "Dino Amadori, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Paolo Bechi, Prof."
                }, 
                "facility": {
                    "address": {
                        "city": "Firenze", 
                        "country": "Italy", 
                        "state": "FI"
                    }, 
                    "name": "Ospedale Careggi"
                }, 
                "investigator": {
                    "last_name": "Paolo Bechi, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Armando Santoro, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Rozzano", 
                        "country": "Italy", 
                        "state": "MI"
                    }, 
                    "name": "Istituto Clinico Humanitas"
                }, 
                "investigator": {
                    "last_name": "Armando Santoro, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Monica Lencioni, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Pisa", 
                        "country": "Italy", 
                        "state": "PI"
                    }, 
                    "name": "Azienda Ospedaliera Universitaria Pisana"
                }, 
                "investigator": {
                    "last_name": "Monica Lencioni, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Franco Roviello, Prof."
                }, 
                "facility": {
                    "address": {
                        "city": "Siena", 
                        "country": "Italy", 
                        "state": "SI"
                    }, 
                    "name": "Policlinico Le Scotte"
                }, 
                "investigator": {
                    "last_name": "Franco Roviello, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Verena De Angelis, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Perugia", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia"
                }, 
                "investigator": {
                    "last_name": "Verena De Angelis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Andrea Ciarlo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Prato", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda USL 4 di Prato"
                }, 
                "investigator": {
                    "last_name": "Andrea Ciarlo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Giacomo Moscati, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale San Filippo Neri"
                }, 
                "investigator": {
                    "last_name": "Giacomo Moscati, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Giovanni De Manzoni, Prof."
                }, 
                "facility": {
                    "address": {
                        "city": "Verona", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Borgo Trento"
                }, 
                "investigator": {
                    "last_name": "Giovanni De Manzoni, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised Phase Ii Study Of Pre-Operative Or Peri-Operative Docetaxel, Oxaliplatin, Capecitabine (Dox) Regimen In Patients With Locally Advanced Resectable Gastric Cancer", 
        "overall_contact": {
            "email": "o.nanni@irst.emr.it", 
            "last_name": "Oriana Nanni, PhD", 
            "phone": "+390543739266"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "the difference in percentage of patients receiving all the planned chemotherapeutic cycles between the two arms.", 
            "safety_issue": "Yes", 
            "time_frame": "7 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01876927"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the percentage of tumors downstaged at the diagnosis, compared with the pathological stage detected at the time of surgery (according to Recist criteria)", 
                "measure": "The percentage of tumors downstaged at the diagnosis", 
                "safety_issue": "No", 
                "time_frame": "7 years"
            }, 
            {
                "description": "Comparation of treatment tolerability and safety and tumor response between patients with pathological stage pT1-3 vs pT0 (detected at the time of surgery)", 
                "measure": "Treatment tolerability and safety and tumor response in patients with pathological stage pT1-3 vs pT0", 
                "safety_issue": "Yes", 
                "time_frame": "7 years"
            }, 
            {
                "measure": "Number of patients with adverse events of grade 3-4 as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "7 years"
            }, 
            {
                "description": "Evaluation of the role of PET as a tool to detect tumor response", 
                "measure": "Diagnostic capability of PET", 
                "safety_issue": "No", 
                "time_frame": "7 years"
            }, 
            {
                "measure": "Efficacy comparation between curative vs palliative surgery", 
                "safety_issue": "No", 
                "time_frame": "7 years"
            }, 
            {
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "7 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "7 years"
            }, 
            {
                "description": "Evaluation of possible correlations between the diagnostic techniques CT scan, CT/PET and laparoscopy", 
                "measure": "Diagnostic capability of CT scan, CT/PET and laparoscopy", 
                "safety_issue": "No", 
                "time_frame": "7 years"
            }, 
            {
                "description": "Biological detection of molecular markers related to treatment toxicity (DPYD, MTHFR, TS, XPD, ERCC1, XRCC1)", 
                "measure": "Biological profile of treatment toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "7 years"
            }, 
            {
                "description": "Biological detection of molecular markers related to treatment prognosis (TYMS, GSTP1, COX-2, RUNX3, methylation profile (Cox2, hMLH1, MGMT))", 
                "measure": "Biological profile of treatment prognosis", 
                "safety_issue": "No", 
                "time_frame": "7 years"
            }, 
            {
                "description": "Biological detection of molecular markers related to therapy response (TYMS, DPYD, MTHFR, OPRT, ERCC1, XRCC1/2/3, GSTP1, GSTM1, GSTT1, ABCB1, methylation profile (Cox2, hMLH1, MGMT), whole genome arrayCGH)", 
                "measure": "Biologcal profile of treatment response", 
                "safety_issue": "No", 
                "time_frame": "7 years"
            }
        ], 
        "source": "Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}